Clinical bottom line
Patients with hepatic encephalopathy (HE) undergoing surgery represent a high-risk group requiring tailored anesthetic management to mitigate perioperative neurological complications and optimize outcomes. Current evidence underscores the importance of careful preoperative neurological assessment, intraoperative brain monitoring, and strategies to minimize cerebral edema and metabolic disturbances. While data specific to non-transplant surgeries remain limited, extrapolation from liver transplantation and cirrhosis cohorts suggests that vigilant perioperative care can reduce adverse neurological events and improve survival. This evidence digest summarizes key findings and highlights areas warranting further validation.
What the evidence shows
Hepatic encephalopathy, a neuropsychiatric syndrome caused by liver dysfunction and portosystemic shunting, predisposes patients to perioperative neurological deterioration, including cerebral edema and intracranial hypertension. Lieber et al. (2020) analyzed anesthesia-related complications in patients with cirrhosis undergoing endoscopic procedures and found increased risks of encephalopathy exacerbation and respiratory depression, emphasizing the need for cautious sedation and airway management. Similarly, Millwala et al. (2007) reported that cirrhotic patients undergoing non-hepatic surgery have elevated morbidity and mortality, particularly when HE is present, highlighting the importance of preoperative optimization.
In liver transplantation, where HE is often severe, perioperative neurological monitoring has advanced. Cremascoli et al. (2025) reviewed innovative brain monitoring techniques, such as near-infrared spectroscopy and transcranial Doppler, which allow real-time assessment of cerebral oxygenation and autoregulation, potentially guiding anesthetic depth and hemodynamic management to prevent brain injury. Tan et al. (2012) demonstrated that pretransplant neurological status predicts posttransplant brain injury severity, underscoring the prognostic value of neurological evaluation.
Older liver transplant recipients with preexisting neurological impairment, including HE, have worse outcomes (Sonny et al., 2015), suggesting that age and neurological status should inform perioperative risk stratification. Although direct evidence on anesthetic agents in HE is sparse, clinical practice favors agents with minimal hepatic metabolism and neurotoxicity, careful titration to avoid oversedation, and avoidance of benzodiazepines which may worsen encephalopathy.
Caveats and uncertainty
The evidence base specific to anesthetic management of HE patients undergoing non-transplant surgery is limited and largely extrapolated from studies in cirrhosis and liver transplantation populations. Many studies are retrospective or observational, with heterogeneous patient populations and surgical procedures, limiting generalizability. The optimal intraoperative brain monitoring modalities and protocols remain under investigation, and their impact on long-term neurological outcomes is not fully established.
Additionally, the pathophysiology of HE is multifactorial, involving ammonia toxicity, inflammation, and cerebral edema, complicating the identification of modifiable anesthetic factors. There is also uncertainty regarding the best anesthetic agents and dosing strategies to minimize HE exacerbation, as randomized controlled trials are lacking. Finally, the interplay between systemic hemodynamics, cerebral perfusion, and liver function in this population requires further elucidation.
How this may change practice
Anesthesiologists should incorporate thorough preoperative neurological assessment for patients with HE, including evaluation of encephalopathy severity and potential precipitating factors. Multidisciplinary collaboration with hepatology and neurology is advisable to optimize medical management before surgery. Intraoperative brain monitoring, where available, may guide anesthetic depth and hemodynamic targets to reduce cerebral complications.
Anesthetic plans should prioritize agents with favorable hepatic profiles and avoid medications known to worsen encephalopathy. Vigilant airway management and respiratory support are critical given the risk of hypoventilation and aspiration. Postoperative monitoring for neurological changes should be intensified to detect early signs of HE exacerbation or cerebral edema.
Future clinical protocols may integrate advanced neuromonitoring and tailored anesthetic regimens to improve outcomes, but these require prospective validation. Until then, individualized risk assessment and cautious perioperative care remain paramount.